CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF PEMBROLIZUMAB IN GREECE: AN MODELING ANALYSIS BASED ON 22 INDICATIONS
Author(s)
Nikolaos T. Yfantopoulos, MSc1, ANASTASIOS SKROUMPELOS, PhD2, Antonis Karokis, MSc2.
1Value and Patient Access Manager, MSD, Alimos, Greece, 2MSD, Athens, Greece.
1Value and Patient Access Manager, MSD, Alimos, Greece, 2MSD, Athens, Greece.
OBJECTIVES: Immuno-oncology (IO) agents have revolutionized cancer management, improving both progression-free and overall survival. The aim of this study is to estimate the population-level health impact and cost-effectiveness of pembrolizumab across 22 approved indications in Greece. The cancer types included are melanoma, lung, renal cell carcinoma, Hodgkin lymphoma, cervical cancer, urothelial cancer, gastric cancer, esophageal and head and neck carcinoma.
METHODS: A single, central model was developed to calculate clinical outcomes and cost effectiveness results generated by separate models for each of the 22 indications. In line with the designs of the corresponding clinical trials, this model compared pembrolizumab with standard of care. The resulting outputs were then used to project clinical outcomes for patients who initiated treatment between 2017 and 2024. To evaluate the cost effectiveness of pembrolizumab across all indications, an aggregate incremental cost-effectiveness ratio (ICER) was calculated by weighting each indication according to its prevalence. The model inputs included efficacy data from clinical trials, invoice drug prices (not including voluntary discounts and paybacks) and the respective cancer management costs from the literature. Outcomes included life-years (LYs), quality-adjusted life-years (QALY’s), events or recurrences, deaths and ICER.
RESULTS: Results indicate that, in the period 2017-2024, 28,668 patients have received treatment with pembrolizumab ; which is estimated to have avoided 3,844 deaths and prevented metastases in 3,811 patients. Pembrolizumab treatment generated an additional 56,408 LY’s and 47,929 QALY’s. The aggregate weighted ICER per LY gained was 38,329€ and 53,580€ per QALY gained, which is below the threshold for Greece according to the World Health Organisation (64,936€/QALY).
CONCLUSIONS: Results indicate that pembrolizumab treatment could provide substantial benefits to cancer patients in Greece by reducing disease progressions, mortality and extending survival for patients. Additionally, pembrolizumab was a cost-effective treatment option for managing cancer in Greece.
METHODS: A single, central model was developed to calculate clinical outcomes and cost effectiveness results generated by separate models for each of the 22 indications. In line with the designs of the corresponding clinical trials, this model compared pembrolizumab with standard of care. The resulting outputs were then used to project clinical outcomes for patients who initiated treatment between 2017 and 2024. To evaluate the cost effectiveness of pembrolizumab across all indications, an aggregate incremental cost-effectiveness ratio (ICER) was calculated by weighting each indication according to its prevalence. The model inputs included efficacy data from clinical trials, invoice drug prices (not including voluntary discounts and paybacks) and the respective cancer management costs from the literature. Outcomes included life-years (LYs), quality-adjusted life-years (QALY’s), events or recurrences, deaths and ICER.
RESULTS: Results indicate that, in the period 2017-2024, 28,668 patients have received treatment with pembrolizumab ; which is estimated to have avoided 3,844 deaths and prevented metastases in 3,811 patients. Pembrolizumab treatment generated an additional 56,408 LY’s and 47,929 QALY’s. The aggregate weighted ICER per LY gained was 38,329€ and 53,580€ per QALY gained, which is below the threshold for Greece according to the World Health Organisation (64,936€/QALY).
CONCLUSIONS: Results indicate that pembrolizumab treatment could provide substantial benefits to cancer patients in Greece by reducing disease progressions, mortality and extending survival for patients. Additionally, pembrolizumab was a cost-effective treatment option for managing cancer in Greece.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO27
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Topic Subcategory
Clinician Reported Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology